Development of Hodgkin Lymphoma in a Patient with Common Variable Immunodeficiency
Istanbul Medical Journal · 2019
DOI: 10.4274/imj.galenos.2018.46514 ↗Kurz gefasst
Fachartikel in der Zeitschrift Istanbul Medical Journal, 2019. Verfasst von Öner Özdemir und 3 weiteren Autor:innen. Die Arbeit wurde bisher 2-mal zitiert (Crossref).
Abstract (Originalsprache)
Common variable immunodeficiency (CVID) is a primary immunodeficiency, which is characterized by insufficiency in the synthesis of immunoglobulins due to the disruption of B cell differentiation.The term "variable" in its name describes the heterogeneous clinical picture (infections, chronic lung disease, autoimmune diseases, gastrointestinal disorders, and malignancy) in this disease.Although the risk of developing malignancy in children with primary immunodeficiency is reported to be 4%, this rate is 10.000 times higher than healthy subjects of similar age.Non-Hodgkin lymphoma (NHL) accounts for 60% of malignancy in primary immunodeficiency patients (1).In the cohorts, the incidence of cancer in CVID patients was 15-21%.The most common malignancy was reported to be NHL, followed by gastric, breast, bladder, and cervix tumors (2-4).Our case shows that Hodgkin lymphoma may rarely develop in CVID and is presented to raise awareness.
Zitieren
APA
Özdemir, Ö., Orhan, M. F., Koçer, G. B., & Büyükavcı, M. (2019). Development of Hodgkin Lymphoma in a Patient with Common Variable Immunodeficiency. Istanbul Medical Journal. https://doi.org/10.4274/imj.galenos.2018.46514
Vancouver
Özdemir Ö, Orhan MF, Koçer GB, Büyükavcı M. Development of Hodgkin Lymphoma in a Patient with Common Variable Immunodeficiency. Istanbul Medical Journal. 2019. doi:10.4274/imj.galenos.2018.46514
BibTeX
@article{zdemir2019,
author = {Özdemir, Öner and Orhan, Mehmet Fatih and Koçer, Gizem Böke and Büyükavcı, Mustafa},
title = {Development of Hodgkin Lymphoma in a Patient with Common Variable Immunodeficiency},
journal = {Istanbul Medical Journal},
year = {2019},
doi = {10.4274/imj.galenos.2018.46514}
}
EUVIMED